Compare FTLF & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTLF | RLYB |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.6M | 89.2M |
| IPO Year | 2006 | 2021 |
| Metric | FTLF | RLYB |
|---|---|---|
| Price | $9.25 | $16.93 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $21.50 | N/A |
| AVG Volume (30 Days) | ★ 11.9K | 7.3K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.37 | ★ 6.16 |
| Revenue | ★ $21,744,000.00 | $858,000.00 |
| Revenue This Year | $45.76 | N/A |
| Revenue Next Year | $5.10 | N/A |
| P/E Ratio | $25.08 | ★ $2.75 |
| Revenue Growth | 11.52 | ★ 43.00 |
| 52 Week Low | $8.67 | $0.48 |
| 52 Week High | $20.98 | $17.57 |
| Indicator | FTLF | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 40.42 | 49.87 |
| Support Level | $8.88 | $16.51 |
| Resistance Level | $9.87 | $17.32 |
| Average True Range (ATR) | 0.35 | 0.41 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 12.41 | 41.98 |
FitLife Brands Inc is a provider of proprietary nutritional supplements for health-conscious consumers. The company markets and sells its products under NDS, PMD, Siren labs, Core active, Metis nutrition, Dr. Tobias, MusclePharm, Irwin Naturals, Applied Nutrition, Isatori, and Nature's Secret brand names. Its product portfolio consists of sports nutrition, energy, sports drink products, meal replacement products, and weight loss products. The firm derives its revenue from product sales. Its product categories include Natural & Organic Foods, Functional Foods, Natural & Organic Personal Care and Household Products, and Supplements.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.